Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

French drugmaker Sanofi has confirmed its plan to spend €1.3bn on an insulin factory at its site near Frankfurt, website ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

As one of the first worldwide suppliers of the influenza vaccines, and now, with over 70 years of innovation in influenza ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

Goldman Sachs, JP Morgan, Morgan Stanley and UBS are global coordinators on the trade, with Barclays, Bank of America, BNP ...

IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against immunology and inflammation targets. For more ...

I highlight potential of Biomea Fusion's diabetes drug amid competition, advises caution with stock due to risks. Read more ...